Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pinus massoniana extract (PMBE) is a natural product derived from the bark of the Chinese red pine (*Pinus massoniana*), a species traditionally used in Chinese medicine. The extract is characterized by a high concentration of bioactive proanthocyanidins, particularly the B series procyanidins, which constitute approximately 26-28% of its composition. PMBE has been extensively studied in preclinical research for its potent anticancer properties across various malignancies, including hepatocellular carcinoma, ovarian cancer, cervical cancer, and breast cancer. Its therapeutic effects are mediated through the induction of apoptosis, cell cycle arrest, and the inhibition of tumor cell migration. Beyond oncology, the extract has demonstrated antioxidant, hepatoprotective, and antihypertensive activities. While it shows promise as a candidate for pharmaceutical development and as a functional food additive, it currently remains in the research and discovery phase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pinus massoniana extract.